Trials / Completed
CompletedNCT00477659
Neural Correlates In Mild Alzheimer's Disease
A Single Center Study To Examine Neural Correlates Of Cognition In Subjects With Mild Alzheimer's Disease After Three Months Of Open Label Donepezil HCl (Aricept® ) Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to identify neural correlates of cognitive improvement after 3 months of donepezil hydrochloride treatment using either or both of two functional magnetic resonance imaging (fMRI) measures - the functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion; in the Medial Temporal Lobe (MTL) network in subjects in the early stage of Alzheimer's Disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil hydrochloride | Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks |
Timeline
- Start date
- 2007-07-23
- Primary completion
- 2008-08-15
- Completion
- 2008-08-15
- First posted
- 2007-05-24
- Last updated
- 2021-11-10
- Results posted
- 2021-11-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00477659. Inclusion in this directory is not an endorsement.